Progress in immunotherapy for small cell lung cancer

doi:10.5306/wjco.v11.i6.370

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 6

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7736)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

410

WORD

214

HTML

4609

Tables (1-1)

592

Sum=5825

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

832

Download

1079

Sum=1911

Jun 24, 2020 (publication date) through Feb 23, 2026

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Clin Oncol. Jun 24, 2020; 11(6): 370-377
Published online Jun 24, 2020. doi: 10.5306/wjco.v11.i6.370

Progress in immunotherapy for small cell lung cancer

Dong Zhao, Bing Xie, Yong Yang, Peng Yan, Sheng-Nan Liang, Qiang Lin

Dong Zhao, Bing Xie, Yong Yang, Peng Yan, Sheng-Nan Liang, Department of Oncology, The People’s Hospital of Lixin County, Bozhou 236700, Anhui Province, China

Qiang Lin, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu 062552, Hebei Province, China

Author contributions: Zhao D participated in the study design and drafted the manuscript; Xie B, Yang Y, Yan P, and Liang SN participated in the drafting of the manuscript and prepared the data; Lin Q designed the study and critically revised the intellectual content and gave final approval of manuscript; All authors issued final approval for the version to be submitted.

Conflict-of-interest statement: There is no conflict of interest associated with any of the senior author or other coauthors contributed their efforts in this manuscript.

Corresponding author: Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, 8 Huizhan Avenue, Renqiu 062552, Hebei Province, China. billhappy001@163.com

Received: February 26, 2020
Peer-review started: February 26, 2020
First decision: March 27, 2020
Revised: April 18, 2020
Accepted: May 12, 2020
Article in press: May 12, 2020
Published online: June 24, 2020
Processing time: 118 Days and 19.2 Hours

Abstract

Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. At present, radiotherapy and chemotherapy remain the mainstay of treatment for SCLC. Progress in targeted therapies for SCLC with driver mutations has been slow, and these therapies are still under investigation in preclinical or early-phase clinical trials, and research on antiangiogenic tyrosine kinase inhibitors (e.g., anlotinib) has achieved some success. Immunotherapy is becoming an important treatment strategy for SCLC after radiotherapy and chemotherapy. In this article we review the recent advances in immunotherapy for SCLC.

Keywords: Small-cell lung cancer; Programmed death-1 inhibitors; Cytotoxic T lymphocyte-associated antigen-4 inhibitors; Poly adenosine diphosphate ribose polymerase inhibitors

Core tip: Small-cell lung cancer (SCLC) is a special type of lung cancer that belongs to highly aggressive neuroendocrine tumors. Classical radiotherapy and chemotherapy have a plateauing effect. Immunotherapy is becoming an important treatment strategy for SCLC. In this article, we review the recent advances in immunotherapy for SCLC.